Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820203 | 0.88 | HTR7 (0.48) | KDM4EALDH1A1LMNAHTR7KMT2A | |
| SCHEMBL820403 | 0.86 | HPGD (0.44) | KDM4EALDH1A1LMNAMAPTHTT | |
| SCHEMBL820406 | 0.86 | HTR7 (0.44) | KDM4EALDH1A1LMNAMAPTHTT | |
| SCHEMBL820183 | 0.83 | L3MBTL1 (0.43) | LMNAHTR7POLBKMT2ASLC6A3 | |
| SCHEMBL820191 | 0.82 | HTR7 (0.45) | ALDH1A1LMNAHTR7POLBKMT2A | |
| SCHEMBL820398 | 0.82 | LMNA (0.43) | ALDH1A1LMNAHTTHTR7POLB | |
| SCHEMBL820625 | 0.77 | L3MBTL1 (0.49) | ALDH1A1LMNAMAPTPOLBKMT2A | |
| SCHEMBL820402 | 0.77 | L3MBTL1 (0.55) | ALDH1A1LMNAMAPTHTTPOLB | |
| SCHEMBL820612 | 0.76 | LMNA (0.47) | KDM4EALDH1A1LMNAMAPTHTT | |
| SCHEMBL820811 | 0.74 | HTR7 (0.40) | ALDH1A1LMNAHTTHTR7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222177-B2 | Catalyst and reaction process | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054190-A1 | CATALYST AND REACTION PROCESS | ME1, MAL2, ME2 | KDM4E 2954/4885ALDH1A1 1375/4885LMNA 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.